A phase II clinical trial of prophylactic application of G-CSF in 38 patients with limited-stage SCLC treated with CCRT did not show an increased risk of acute or advanced pulmonary toxicity or grade III-IV acute esophagitis, nor did it result in treatment-related mortality in patients. The gene discussed is CSF3; the disease is small cell lung carcinoma.